A detailed history of Charles Schwab Investment Management Inc transactions in Celcuity Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 221,671 shares of CELC stock, worth $2.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
221,671
Previous 67,959 226.18%
Holding current value
$2.5 Million
Previous $1.11 Million 196.95%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$13.98 - $19.15 $2.15 Million - $2.94 Million
153,712 Added 226.18%
221,671 $3.31 Million
Q2 2024

Aug 12, 2024

BUY
$14.1 - $20.78 $319,308 - $470,583
22,646 Added 49.98%
67,959 $1.11 Million
Q1 2024

May 08, 2024

BUY
$13.74 - $21.6 $494 - $777
36 Added 0.08%
45,313 $978,000
Q4 2023

Feb 06, 2024

SELL
$8.7 - $15.02 $16,303 - $28,147
-1,874 Reduced 3.97%
45,277 $659,000
Q3 2023

Nov 08, 2023

BUY
$8.96 - $10.75 $25,329 - $30,390
2,827 Added 6.38%
47,151 $430,000
Q2 2023

Aug 09, 2023

BUY
$9.39 - $12.18 $416,202 - $539,866
44,324 New
44,324 $486,000
Q2 2022

Aug 15, 2022

SELL
$5.35 - $10.11 $145,926 - $275,760
-27,276 Closed
0 $0
Q1 2022

May 13, 2022

BUY
$7.93 - $13.33 $15,772 - $26,513
1,989 Added 7.87%
27,276 $256,000
Q3 2021

Nov 16, 2021

BUY
$17.35 - $24.87 $102,052 - $146,285
5,882 Added 30.31%
25,287 $456,000
Q2 2021

Aug 16, 2021

BUY
$14.25 - $30.93 $276,521 - $600,196
19,405 New
19,405 $466,000
Q2 2020

Aug 14, 2020

SELL
$4.42 - $11.04 $65,013 - $162,387
-14,709 Closed
0 $0
Q2 2019

Aug 09, 2019

BUY
$19.88 - $25.0 $26,022 - $32,725
1,309 Added 9.77%
14,709 $368,000
Q3 2018

Nov 13, 2018

BUY
$20.96 - $30.77 $52,400 - $76,925
2,500 Added 22.94%
13,400 $386,000
Q2 2018

Aug 08, 2018

BUY
$16.13 - $26.99 $175,817 - $294,191
10,900 New
10,900 $271,000

Others Institutions Holding CELC

About Celcuity Inc.


  • Ticker CELC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,941,300
  • Market Cap $169M
  • Description
  • Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...
More about CELC
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.